Altamira Therapeutics Ltd. (CYTOF)
CIK 1601936 · operating company. SEC filings, financial statements, 10-K sections, 8-K items and insider trades for Altamira Therapeutics Ltd..
Recent SEC filings
| Filed | Form | Accession number |
|---|---|---|
| Feb 27, 2026 | 15-12G | 0001213900-26-021580 |
| Aug 29, 2025 | 6-K | 0001213900-25-082071 |
| Jun 17, 2025 | 25-NSE | 0001354457-25-000544 |
| Jun 17, 2025 | 25-NSE | 0001354457-25-000544 |
| Jun 11, 2025 | 6-K | 0001213900-25-053451 |
| May 15, 2025 | SCHEDULE 13G/A | 0001172661-25-002248 |
| May 9, 2025 | 6-K | 0001213900-25-041560 |
| May 6, 2025 | SCHEDULE 13D/A | 0001213900-25-039888 |
| Apr 30, 2025 | 6-K | 0001213900-25-037097 |
| Apr 30, 2025 | 20-F | 0001213900-25-037199 |
| Apr 4, 2025 | S-8 | 0001213900-25-029036 |
| Mar 10, 2025 | 6-K | 0001213900-25-022236 |
| Feb 14, 2025 | SCHEDULE 13G/A | 0001172661-25-001302 |
| Dec 20, 2024 | 6-K | 0001213900-24-110771 |
| Nov 14, 2024 | SC 13G | 0001172661-24-005081 |
| Oct 4, 2024 | 6-K | 0001213900-24-085537 |
| Sep 24, 2024 | 6-K | 0001213900-24-081199 |
| Sep 19, 2024 | 6-K | 0001213900-24-080300 |
| Sep 18, 2024 | 424B4 | 0001213900-24-079889 |
| Sep 17, 2024 | EFFECT | 9999999995-24-002863 |
| Sep 16, 2024 | F-1/A | 0001213900-24-078764 |
| Sep 16, 2024 | F-1/A | 0001213900-24-078891 |
| Aug 22, 2024 | F-1 | 0001213900-24-071896 |
| Jul 12, 2024 | EFFECT | 9999999995-24-002147 |
| Jul 8, 2024 | POS AM | 0001213900-24-059862 |